2025-05-15 - Analysis Report
Okay, here's a comprehensive analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the provided data, presented in English with a focus on numerical data and concise analysis:

**RXRX Stock Analysis**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** RXRX
*   **Company:** Recursion Pharmaceuticals Inc. - A clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.
*   **Cumulative Return (RXRX):** 0.0
*   **Cumulative Return (VOO):** 0.0
*   **Divergence:**
    *   **Max:** 0.0
    *   **Min:** 0.0
    *   **Current:** 0.0
    *   **Relative Divergence:** 0.0

**Analysis:** RXRX's performance mirrors the S&P 500 exactly (at 0.0 return), showing no outperformance or underperformance within the provided period. The relative divergence is at its minimum, indicating the stock is performing at the lowest end of its historical range relative to the S&P 500.

*   **Alpha/Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 0.0% | 0.0% | 0.0% | 1.0 | 3.8 |
| 2022-2024  | 0.0% | 0.0% | 0.0% | 1.0 | 2.6 |
| 2023-2025  | 0.0% | 0.0% | 0.0% | 1.0 | 1.8 |

**Analysis:**  A Beta of 1.0 suggests RXRX's volatility aligns with the market. An Alpha of 0.0 indicates no excess return beyond market movements. CAGR and MDD are 0.0%, implying no growth and no drawdowns within the data provided.

**2. Recent Stock Price Movement**

*   **Current Price:** 4.51
*   **Last-Market Data:** {'price': 4.31, 'previousClose': 4.51, 'change': -4.43}
*   **5-Day Moving Average:** 4.412
*   **20-Day Moving Average:** 5.194
*   **60-Day Moving Average:** 6.1061

**Analysis:** The stock price has decreased in the last day, indicated by negative changes. The price is below all moving averages, suggesting a short-term, mid-term, and long-term downward trend.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.0 (Indicates Low Risk)
*   **RSI:** 32.85 (Approaching oversold territory, typically below 30)
*   **PPO:** -1.44 (Indicates a downtrend)
*   **Recent (20-Day) Relative Divergence Change:** 0.0 (Negative, confirming short-term decline)
*   **Expected Return:** 0.0%

**Analysis:** The RSI suggests the stock is nearing oversold conditions. Negative PPO and negative relative divergence change further suggest a bearish trend.  The negative change percentage from 'previousClose' to 'price' is significant, indicating a sharp drop in recent market activity. Market risk indicator indicates low risk and expected return is 0.0%.

**4. Recent News & Significant Events**

*   **2025-05-11:**  Major business developments, regulatory changes, or market events.
*   **2025-05-13:** Analyst discussions on performance, industry trends, and economic factors.
*   **2025-05-14:**  Stock volatility due to recent news, earnings reports, or executive actions.
*   **2025-05-12:** Market expert risk and opportunity assessment; investor monitoring advised.

**Analysis:** Recent news events suggest possible catalysts for increased volatility and potential shifts in investor sentiment. Keep abreast of Recursion Pharmaceuticals Inc's press releases and regulatory updates.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-05-05 | -0.5  | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2024-08-08 | -0.4  | 0.01 B$   |
| 2024-05-09 | -0.39 | 0.01 B$   |
| 2025-05-05 | -0.39 | 0.01 B$   |

**Analysis:**  The company is consistently reporting negative EPS, indicating losses. Revenue is consistently low, suggesting the company is not yet generating substantial income from its products or services.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |
| 2024-03-31 | $0.01B  | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-03-31 | $0.93B  | -21.68%  |
| 2024-12-31 | $1.03B  | -17.29%  |
| 2024-09-30 | $0.52B  | -18.27%  |
| 2024-06-30 | $0.58B  | -16.69%  |
| 2024-03-31 | $0.40B  | -22.78%  |

**Analysis:**  Revenue is fluctuating and generally low. Profit margins are often negative, indicating inefficiency in turning revenue into profit. Negative ROE suggests that the company is not effectively using shareholder equity to generate profits. The company's equity has fluctuated, but it is relatively high.

**7. Overall Summary**

RXRX shows a concerning financial picture.  While the Market Risk Indicator suggests low risk, the negative earnings, inconsistent revenue, and negative profit margins raise red flags. Technically, the stock is in a downtrend and approaching oversold conditions. The recent news events could introduce volatility.  Investors should exercise caution and conduct thorough due diligence, paying close attention to the company's upcoming earnings reports and any significant announcements related to its business development, regulatory changes, or product pipeline.
